Truist Financial analyst Jailendra Singh maintains $IQVIA Holdings (IQV.US)$ with a buy rating, and sets the target price at $265.
According to TipRanks data, the analyst has a success rate of 27.5% and a total average return of -17.7% over the past year.
Furthermore, according to the comprehensive report, the opinions of $IQVIA Holdings (IQV.US)$'s main analysts recently are as follows:
Iqvia's third quarter performance surpassed expectations primarily due to its TAS segment's impressive results. However, this success is currently overshadowed by challenges faced within the R&DS area, including a significant project cancellation and the postponement of two major trials until 2025. Despite these headwinds, the perceived value versus risk remains compelling following the stock's recent decline.
The company indicated that the market remains relatively stable, highlighting that the challenges with bookings are arising from delays and drug failures, rather than significant effects from pipeline rationalization.
The company has encountered a challenging industry operating environment. Comments from the company indicate that pharma portfolio reprioritizations related to the IRA may be concluding, and the company seems to be gaining from the pharmaceutical industry's vendor consolidation trend.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
储亿银行分析师Jailendra Singh维持$艾昆纬 (IQV.US)$买入评级，目标价265美元。
根据TipRanks数据显示，该分析师近一年总胜率为27.5%，总平均回报率为-17.7%。
此外，综合报道，$艾昆纬 (IQV.US)$近期主要分析师观点如下：
艾可维亚第三季度表现超出预期，主要是由于其TAS板块出色的业绩。然而，目前这一成功被研发服务（R&D）领域内面临的挑战所掩盖，包括一项重要项目的取消以及两项重要试验直到2025年才能进行。尽管存在这些阻力，但股票最近下跌后，价值与风险的认知仍然令人信服。
该公司表示市场仍然相对稳定，并强调预订方面的挑战主要来自延误和药品失败，而非管道合理化的显著影响。
该公司遭遇了一个充满挑战的行业营运环境。公司的评论表明，与药品组合重新排序相关的IRA可能即将结束，公司似乎正在受益于药品行业的供应商整合趋势。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
